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The number of reported cases of smooth muscle tumor (SMT) arising in patients with AIDS has been increasing since the
mid-1990s. The aim of this study is to characterize the epidemiology, clinical manifestations, pathologic features, prognosis
and, management of Epstein-Barr virus-related SMT (EBV-SMT) in patients with AIDS. An English language literature search
identiﬁed 53 articles including 64 reported cases of EBV-SMT. The majority of these reports involved patients who were young,
severely immunosuppressed, and had multifocal tumors. The central nervous system was the most common site to be involved.
Histologically, tumors had smooth muscle features and were immunoreactive for muscle markers and all but two tumors
demonstrated the presence of EBV by either immunohistochemistr y ,i ns i t uh y b r i d i z a t i o n ,a n d / o rP C R .W h i l em i t o s e sa n d / o r
necrosis were used to separate leiomyomafrom leiomyosarcoma,these features did not correlate with clinicaloutcome. Treatment
included primarily resection, and less often radiotherapy, chemotherapy and highly active antiretroviral therapy (HAART).
Overall, EBV-SMTs appear to have variable aggressiveness and clinical outcome and may exhibit a more favorable prognosis
compared to conventionalleiomyosarcoma.Tumor-related death from EBV-SMT occurred in only 4 of 51 patients.
1.Introduction
An increased rate of both acquired immune deﬁciency
syndrome (AIDS) deﬁning cancers (e.g., Kaposi sarcoma,
B-cell non-Hodgkin lymphoma, uterine cervical neoplasia)
and non-AIDS deﬁning cancers (NADC) like Hodgkin
lymphoma, anal cancer, and lung cancer is a well estab-
lished phenomenon in patients with AIDS. As the human
immunodeﬁciency virus (HIV) pandemic persists and more
people are living with chronic HIV infection, the rate and
spectrum of NADC continue to grow. There are increasing
numbers ofcase reports and small case series inthe literature
documenting the occurrence of smooth muscle tumors
(SMT) in the adult and pediatric population suﬀering from
AIDS. In fact, SMTs including malignant leiomyosarcoma,
prior to the AIDS epidemic, were exceedingly rare in the
pediatric population. Now, SMTs appear to be the sec-
ond most common type of neoplasm arising in children
with AIDS [1–3]. EBV-SMT also occurs in posttransplant
immunosuppressed patients and individuals with other
causes of immunosuppression such as autoimmune disease
and common variable immunodeﬁciency syndrome [4, 5].
Coinfection with Epstein-Barr Virus (EBV) appears to be
a necessary cofactor for the development of these tumors.
Hence, these tumors have aptly been termed EBV-associated
SMT (or EBV-SMT). The association of EBV and SMT in
immunocompromised patientswas ﬁrst reported in theearly
1990s.Sincethentherehavebeenmany casereportsofAIDS-
related EBV-SMT ranging from leiomyoma to leiomyosar-
coma (LMS). The pathogenesis of EBV-SMT is related to the
infection and neoplastic transformation of smooth muscle
cells by EBV with clonal expansion. However, the exact
mechanism of tumorigenesis is still unclear. It has been
reported that these tumors tend to be multifocal with the
propensity to arise in virtually any anatomical location.
The clinicopathological features of these unique myogenic
neoplasms in relation to their biological behavior and man-
agement remains to be fully elucidated. To date, there has2 Pathology Research International
beennocomprehensiveevaluationofthepublishedliterature
on EBV-SMT arising in persons with AIDS. Therefore, the
aim of this paper is to review the literature describing SMT
occurring in patients with HIV/AIDS in order to character-
ize their epidemiology, clinical manifestations, pathological
features, prognosis, and management.
2.Methods
A literature review was performed using PubMed as well
as cited references within previously published articles and
textbooksforallpublishedcasesofSMTinpatientswithdoc-
umented HIV infection published in the English language
literature. An attempt was made to avoid duplicate cases
published in the literature. Data accrued from patients with
HIV/AIDS with at least one SMT included publication date
and the authors’ country of origin, patient demographics
(age, gender), HIV details such as mechanism of HIV
acquisition, CD4 cell count (cells/μL), HIV plasma RNA
level (copies/mL), time to detection/manifestation of SMT
from HIV diagnosis (months), tumor type (leiomyoma,
leiomyosarcoma or LMS, other SMT subtype), SMT clinical
and gross pathology ﬁndings (anatomical site, number
of tumors present, size in cm), histopathology (number
of mitoses/10 high power ﬁeld or HPF and presence of
necrosis), immunohistochemical ﬁndings, EBV status by
EBV-encoded RNA (EBER) or PCR, therapeutic modality
and outcome (recorded as alive with no evidence of disease,
alive with disease, dead of disease, dead of another cause,
or lost to follow up; measured in months). The data was
tabulated and analyzed using descriptive statistics.
3.Results
A total of 53 articles were retrieved [1–53], that reported
details on 64 conﬁrmed HIV positive patients with SMTs.
Although EBER was negative in two SMT cases [9, 19]
and EBV testing of the tumors were not performed in ﬁve
patients [8, 37, 42], these HIV-related SMT were included
in this paper. Also included was one case of an EBV-positive
myopericytoma [35]. The publications on SMT in HIV-
infected individuals spanned a 20-year period (1990–2010),
with an equal number being published before and after the
year 2000.
3.1. Pathogenesis. EBV is a member of the gamma subfamily
of herpesvirus. The EBV genome has more than 100 genes,
but only a few are relevant in transmission and replication,
including the latent membrane proteins (LMP1, LMP2A,
and LMP2b), EBV nuclear antigens (EBNA1, EBNA2,
EBNA3A, EBNA3B and EBNA3C), and EBV early RNAs
(EBER1, and EBER2). EBV is associated with a number of
neoplasms in AIDS patients, including Burkitt and Hodgkin
lymphoma.
Primary infection with EBV mainly takes place in the
oropharynx where the virus undergoes lytic replication
during which viral progeny are released. EBV may also
initiateactivelatency,inwhichoneofthreetypesofrestricted
gene expression programs are established. Type I latency
has limited expression only to EBER and EBNA1 and is
the latency program seen in Burkitt lymphoma. The type II
latency program also includes the latent membrane proteins
and is seen typically in nasopharyngeal carcinoma. Type
III latency demonstrates expression of LMPs along with
all EBNAs and is seen in posttransplant lymphoprolifera-
tive disorders (PTLD). PTLD expresses EBNA-2 which is
required for the immortalization of B-cells in culture and
is associated with B-cell proliferation. Like PTLD, several
cases of EBV-SMT have been shown to express EBNA-2
[14, 20, 39, 40]. LMP was mainly negative in HIV-related
SMT.Onlyonecasedemonstratedweakpositivity withLMP-
1[ 22]. It may be that LMP expression is below that detected
by immunohistochemistry in these tumors. Although there
weresomeinconsistentresultsincasestestedforEBNA-2and
LMP-1 [7, 19, 20, 22, 27, 30, 45], it would appear that overall
EBV-SMT demonstrate Type III latency.
Pathogenesis appears to be related to infection and
transformation of smooth muscle cells by EBV. The EBV
receptor CD21 was demonstrated on smooth muscle cells
in nine tumors, suggesting that EBV entry may occur via
this receptor [2, 28, 40]. Some studies found higher levels
of CD21 in tumor cells from EBV-SMT in AIDS patients
than tumor cells from non-AIDS related smooth muscle
neoplasms and normal muscle [2]. This may represent
upregulation of the EBV receptor on smooth muscle cells
in patients with AIDS [2, 3, 28, 40]. Although increased
CD21 expression has not been universally demonstrated, the
possibility of transient expression of this receptor prior to
neoplastic transformation cannot be excluded. Interestingly,
studies attempting to demonstrate CD21 in posttransplant
smoothmuscletumorshavebeenunsuccessful[40].Another
possibility is that infection occurs via fusion of smooth
muscle cells with EBV-infected lymphocytes [46, 47].
Having entered a smooth muscle cell, it is unclear how
EBV infection causes neoplastic transformation with clonal
proliferation.Severalstudieshavedemonstratedtheclonality
of EBV-SMT [2, 26, 40, 48], indicating viral infection of
the cell prior to clonal expansion and implicating EBV in
tumorigenesis. In patients with multiple EBV-SMT, analysis
of clonality demonstrated the presence of diﬀerent clones
in tumors from diﬀerent locations [2, 26, 28, 40, 48].
This supports the hypothesis that multifocal disease is the
result of multiple, independent primary lesions rather than
metastases. Furthermore, each lesion is likely a separate
infection event. Studies looking at EBV copy numbers in
EBV-SMT have found variable results and it has been
suggestedthatthisvariationistheresultofEBVbeingpresent
in the lytic or latent phase [2, 7, 8]. One could expect that
patients with active replicating EBV will have EBV detectable
in their serum [18, 22, 25, 32, 33].
3.2. Epidemiology Findings. The majority (19 of 35 papers,
54%) were published from the USA (see Table 1). Fewer
papers were from Asia (20%) including Thailand, Hong
Kong, Singapore, and Taiwan, as well as from Europe (17%),
from countries like Spain and France. Rare articles were
published by authors from Canada and South America
(Argentina, Peru).Pathology Research International 3
Table 1: Countries reporting SMT in patients with HIV/AIDS.
Region Country # of Publications # of SMT cases
North America USA 19 38
Canada 1 1
Asia
Thailand 3 11
Hong Kong 2 3
Taiwan 1 1
Singapore 1 1
Europe France 4 5
Spain 2 2
South America Argentina 1 1
Peru 1 1
3.3. Clinical Features. Patients were on average 25 years of
age (range, 2.7 to 49 years). Most (66%) were over 20
years old, only three patients (5%) were between the ages
of 10 and 20 years, and the rest (30%) were younger than
10 years of age (see Table 2). These ﬁndings are similar to
two recent series of EBV-SMT in patients with AIDS that
reported a greater proportion of patients over the age of
30 years [18, 26]. In general, smooth muscle neoplasms are
rare in children, but as previously highlighted by others
and our analysis, SMT are disproportionately represented
in children with AIDS [1, 3, 28]. Diﬀerences in gender
were not borne out by these data. In those under 10 years
old, the male:female ratio was approximately 1:2. For the
entire group, very little diﬀerence in gender was noted, with
an overall male:female ratio of 1.3:1 (see Table 2). In 18
patients (28%) HIV infection was acquired by congenital
transmission; in theremainderof thecases HIVwas acquired
by other means (not speciﬁed). Mean CD4 count (missing
data in 19 cases) was approximately 60cells/μL( r a n g e0 –
330cells/μL). The mean HIV viral load (data available
in only 12 cases) was 203,302copies/mL (range, <50 to
>750,000copies/mL). In three cases, treatment described the
use of antiretroviral therapy.
The CNS was a common location, and patients with
these tumors often presented with signiﬁcant neurologic
symptoms [7, 8, 11, 14–17, 20, 24]. EBV-SMT should be
included in the clinical diﬀerential diagnosis for an intracra-
nial or spinal mass arising in a patient with AIDS, which
may be amenable to surgical intervention. Patients with
EBV-SMT may present with a variety of symptoms based
upon tumor location or they may be detected incidentally
during imaging studies or at autopsy. EBV-SMT of the
gastrointestinal tract, for example, may present with bleed-
ing, abdominal pain, obstruction and perforation [37, 42–
44]. Based on published ﬁndings, EBV-SMT has a nodular,
centrally ulcerated appearance on endoscopic examination
[42]. Those with endobronchial tumors may present with
cyanosis, fever, and/or pulmonary infections unresponsive
to antibiotics [6, 19, 34]. Endobronchial tumors, if large
enough, may be visualized on bronchoscopic examination
and surgically ablated.
In 33 cases, there were multiple SMT, eitherconcurrently
or sequentially, and in 20 cases these tumors manifested as
Table 2: Age and gender distribution of SMTs in patients with
HIV/AIDS.
Patient age (years) Male Female
<10 7 12
10–20 1 2
>20 28 14
TotalCases 36 28
solitary lesions. Data on the number of tumors found in
patients was unavailable in 12 cases. Multifocal involvement
is unusual in smooth muscle neoplasms arising in immuno-
competent individuals and is an important feature of EBV-
SMT in AIDS patients. The tumor site and frequency (based
upon available data in 53 patients) is shown in Figure 1.
EBV-SMT involved almost every body location. In cases
where there were greater than ﬁve tumors per patient, sites
of involvement included the brain, lung, liver, adrenals,
colon, and soft tissue. In six cases the diagnosis of EBV-SMT
was detected only at autopsy. The CNS (brain in 19 cases
and spinal cord in 5 cases) is the most common reported
location (Figures 2 and 3). Within the CNS, SMT may be
dural, epidural, or extradural. Rare cases involved the basal
ganglia [11] and pontine cistern [15]. Lung SMT was the
second most common tumor reported (Figures 4 and 5).
SMT in both peripheral (thigh, gluteal, abdominal wall) and
axial (paraspinal) soft tissue sites were reported. All parts of
the gastrointestinal tract were involved from the tongue (2
cases), to palatine tonsil (1 case), stomach, small intestine,
gallbladder and colon. Bone involvement was documented,
mainly of the vertebrae, and in these cases patients had SMT
of multiple body sites. Within the larynx, SMT developed in
the vocal cord. Genitourinary tract SMT was infrequently
reported, including renal involvement in one patient and
multiple tumors of the vulva in a 31-year-old female [23].
SMT of the serosal membranes were seen in the pleura
and pericardium. The time from HIV diagnosis to SMT
presentation ranged from under 1 month to 18 years. There
was little diﬀerence between tumors that presented within
one year and after one year of an HIV diagnosis with respect
to the patient age, CD4 count, number of tumors, or patient,
outcome.
EBV-SMTs appear to arise when patients exhibit modest
immunosuppression due to their underlying HIV infection,
given that the mean CD4 count was 60cells/μLi nt h i ss t u d y .
In only 3 of the 42 cases in which the CD4 levels were
available did patients have CD4 cell counts ≥200cells/μL.
Although it is diﬃcult to determine the exact relationship
between SMT and HIV viremia based upon data available
in only 12 cases, the HIV viral load was on average around
203,302copies/mL. The time from HIV diagnosis to SMT
presentation ranged from under 1 month to 18 years. While
more than two thirds of cases were diagnosed within 4
years of an HIV diagnosis, it is likely that chronic HIV
infection may play an indirect role. Patients with LMS not
only had lower CD4 cell counts, but also more chronic HIV
infection.4 Pathology Research International
CNS (brain and spinal cord) N = 24
Soft tissue N = 22
Lung N = 12
Liver N = 11
Adrenal N = 8
Hematopoetic (spleen (4), lymph nodes (3)) N = 7
Head and neck (oropharynx (4), nose/sinus (1), larynx (3),
eye/orbit (3)) N = 11
Bone N = 3
Other less frequent sites (gallbladder (1), genital tract
(1), kidney (1), serosal membranes (2)) N = 5t o t a l
GI tract (large intestine (9), small intestine (4), stomach (3))
Figure 1: Anatomic location of SMT in HIV-infected patients.
3.4. Pathology Findings. Ten patients were diagnosed with
leiomyoma, 25 with LMS, and in 28 cases the SMT was not
further characterized, including those cases where tumors
were reported to be a SMT of undetermined malignant
potential (SMT-UMP). The characteristics of benign and
malignant SMT are summarized in Table 3.L e i o m y o m aw a s
more common in males. Patients with LMS had higher CD4
cell counts and a longer time to presentation. Tumors (in 30
cases with available published data) ranged in size from 0.5
to 14cm.
Histologically, EBV-SMT demonstrated interlacing fasci-
clesof mild to moderately pleomorphic cigar-shaped spindle
to oval cells with ample eosinophilic cytoplasm (Figure 6).
With electron microscopy, EBV-associated smooth mus-
cle neoplasms demonstrated spindle cells with abundant
cytoplasmic actin microﬁlaments with linearly arranged
pinocytic vesicles [6, 7, 17, 20]. Some cases described a mild
to moderate increase in cellularity and a second population
of small round cells with irregular nuclear contours that
displayedasmoothmusclephenotype[26,29,48].Otherfea-
tures that have been described include a hemangiopericytic
pattern with dilated and branching capillaries and chronic
inﬂammatory cells including intratumoral T lymphocytes
[22, 26, 29, 35, 36, 48]. In some cases, tumors appeared to
Figure 2:Cranialcomputedtomography(CT) scanshowinga4cm
enhancing extradural EBV-SMT at the medial aspect of the right
tentorium cerebelli, with erosion of the petrous apex and extending
into the right optic canal, prepontine cisterns and encasing
right carotid (cavernous portion) artery (image reproduced with
permission from [13]. The AIDS Reader, UBM Medica).
Figure 3: A T1-weighted MRI scan of the spinal cord showing two
enhancing extradural hypointense EBV-SMT, approximately 3cm
and 1cm in diameter, present at the right neural foramina of L3
and S1, respectively (image reproduced with permission from [13].
The AIDS Reader, UBM Medica).
originate from vessel walls, which the authorsbelieved might
explain the multiplicity of these tumors [26, 48].
Histopathological evaluation of these tumors did not
reveal overt features of malignancy in the vast majority
of reports. Patients rarely presented with both benign and
malignant SMT [12, 28]. Deﬁnitive criteria for determining
malignancy of smooth muscle neoplasms arising outside
the gynecologic, genitourinary and gastrointestinal tractsPathology Research International 5
Table 3: Clinicopathological characteristics of benign and malignantEBV-SMT (data from available published cases).
Tumor Leiomyoma Leiomyosarcoma
Number of cases 10 25
Patient age average (range) in years 11 (2–36) 20 (5–48)
Male patients 7 8
Female patients 3 17
CD4 cell count mean (cells/μL) 44.5 60
Time to presentation (months) 42.8 57
Tumor size (cm) 0.5–5 1–7
Tumor site
Brain, lung, liver, spleen,
adrenal, node, soft tissue,
extremity
Brain, spinal cord, lung, liver, spleen, adrenal,
gastrointestinal tract, vertebrae, node, soft tissue,
extremity, serosa, eye, ethmoid sinus, vulva
Solitary tumor 3 9
Multiple tumors 7 11
Patient fatal outcome 6 8
Figure 4: Chest radiography showing an extrapleural EBV-SMT at
the apical area of the right lung (image reproduced with permission
from [13]. The AIDS Reader, UBM Medica).
have yet to be ﬁrmly established [54]. It is unclear if
published guidelines and recommendations for diagnosing
LMS were adhered to in all papers. While tumor size,
cellularity, cytologic atypia, necrosis, and hemorrhage may
correlate with the malignant behavior of SMTs, the most
dependable predictor is the level of mitotic activity [54].
The reported mitotic ﬁgure count (34 cases) ranged from
0–19mitoses/10HPF. In 59% of cases there were 2 or less
mitoses/10HPF recorded. Ki67 was performed in three
cases and showed a proliferation index from 2-3% (solitary
brain LMS) to 12% (vulva LMS) and 18% (SMT of the
orbit). Tumor necrosis was an uncommon ﬁnding as it was
described in only 3 cases. It was noted in two patients with
LMS, one in the adrenal gland of a patient that was still alive
20 months later [4], in the colon and rectum of a 7-year-old
Figure 5: Fiberoptic bronchoscopic examination showing an
endobronchial lobulated leiomyoma that obstructed the ostium of
t h eu p p e rl o b ei na nH I V - p o s i t i v ep a t i e n t( i m a g ec o u r t e s yo fD r .
Humberto Metta).
Figure 6:HistopathologyofanEBV-associatedleiomyosarcomasof
the gallbladder is composed of fascicles of mildly atypical spindle
cells with blunt-ended nuclei and eosinophilic cytoplasm (H&E
stain).6 Pathology Research International
Figure 7: EBV-associatedsmoothmuscletumoris stronglypositive
for alpha smooth muscle actin (immunohistochemicalstain).
Figure 8:In situhybridization forEpstein-Barr virusencoded RNA
(EBER) shows positive (blue) staining in the tumor cell nuclei.
girl alive with her tumors 36 months later [42], and reported
to be only focal in a patient with multiple lung SMT-UMPs
[34].
3.5. Ancillary Study Results. A wide array of immunohisto-
chemical stains were performed in these studies. The results
of immunostains showing positive immunoreactivity are
shown in Table 4. Most cases showed positive immunore-
activity for smooth muscle markers (Figure 7). In the cases
where desmin was reported to be positive, 22 tumors had
only rare or focal staining. The use of other muscle markers
like caldesmon and calponin were attempted in only rare
cases. The immunostains reported to demonstrate negative
staining included S100 (27 cases), CD34 (17 cases), EMA
(15 cases), HMB45 (11 cases), CD99 (11 cases), Factor VIII
(8 cases), cytokeratin (5 cases), c-kit (5 cases), Factor XIII
(2 cases), CD31 (2 cases), LNA-1 (2 cases), CD68 (2 cases),
G F A P( 2c a s e s ) ,U l e x( 1c a s e ) ,C D 2 3( 1c a s e ) ,C D 1 0( 1c a s e ) ,
NSE (1 case), ER (1 case), PR (1 case), p53 (1 case), and
AFP (1 case). Although immunoreactivity for estrogen and
progesterone receptors was only evaluated in one study and
reported to be negative in SMT, a hormonal dependent
Table 4: Immunohistochemical stains with positive immunoreac-
tivity in EBV-SMT.
Immunostain Positive cases Negative cases
Smooth muscleactin (SMA) 39 0
alpha-smoothmuscle actin
(AMA) 17 0
Muscle-speciﬁc actin (MSA) 9 0
Desmin 42 6
Vimentin 5 2
CD21 (C3d Receptor; EBV
receptor) 92
Caldesmon 1 0
Myosin Smoothmuscle heavy
chain (SMHC) 10
Calponin 1 0
mechanism is likelynot involved in the developmentof these
tumors [24].
In studies in which electron microscopy was performed,
no nuclear viral particles were detected and the ﬁndings
were in keeping with a smooth muscle neoplasm [4, 6,
7, 20, 24, 37]. The demonstration of EBV within SMT
(Figure 8)was performed in 57 of63 casesin these published
reports and was proven by a positive EBER (96% of
tested cases), immunohistochemistry for EBNA (with strong
immunoreactivity in 3 of 4 cases) and PCR (3 of 3 cases
positive). The presence of high copy numbers of EBV in
tumor cells by quantitative PCR was found to be consistent
with results of in situ hybridization tests [28]. It has been
suggested that the presence of CD21 (EBV receptor) on
smooth muscle cells is a putative prerequisite for EBV
infection [55], but this is unlikely since the mechanism
of EBV entry into diﬀerent cell types may be by diﬀerent
routes, and it is also uncertain whether the CD21 antigen
found on smooth muscle cells is similar to that found on B
lymphocytes [56]. Immunohistochemical staining for LMP-
1 in addition to EBER was performed in 7 cases [16, 19,
20, 22, 27, 30]. Only one of the cases demonstrated weak
immunoreactivity for LMP-1 [22]. One of these cases, an
endobronchial leiomyoma arising in a patient with AIDS,
was negative for LMP-1 and EBER [19]. The presence of
EBV in SMT cells not only supports a role for this herpes
virus in the pathogenesis of these tumors, butalso serves as a
useful diagnostic marker. EBER in situ hybridization should
probably be performed on any smooth muscle neoplasm
arising in an immunocompromised patient. Classical LMS
and leiomyomas arising in immunocompetent patients have
not demonstrated an association with EBV [2, 30, 49, 50].
3.6. Diﬀerential Diagnosis. The diﬀerential diagnosis of
a spindle cellneoplasm arising in thesetting ofHIVinfection
includes Kaposi sarcoma and mycobacterial spindle cell
pseudotumor. Kaposi’s sarcoma is immunoreactive with
endothelial cell markers such as CD31 and CD34, and
negative for muscle speciﬁc antibodies. Kaposi sarcomaPathology Research International 7
lesional cells are also strongly immunoreactive for LNA-1
(antibody directed against Kaposi sarcoma Human Virus),
whereas EBV-SMT is not [25–27, 35, 38]. In mycobacterial
spindle cell pseudotumor, numerous acid-fast bacilli can be
demonstrated within the spindle cells. EBV-SMT did not
demonstrate any acid fast bacilli in cases in which a Ziehl-
Neelsen stain was performed [15, 22, 37]. Also, unlike
SMT, mycobacterial spindle cell lesions are CD68 positive.
Other spindle-cell tumors that can be mistaken for EBV-
SMT include gastrointestinal stromal tumors (GIST) and
follicular dendritic cell (FDC) sarcomas. Although there is
some overlap in the immunoproﬁles of GIST and EBV-SMT,
CD34 and CD117 (c-kit) are speciﬁc markers of GIST which
were reported to be negative in several cases of EBV-SMT.
FDCsarcoma isarare tumorarising fromfolliculardendritic
cells. Like EBV-SMT, an association with EBV has been
demonstrated in these sarcomas. FDC sarcoma is composed
of eosinophilic spindle cells arranged in fascicles and sheets
and can be distinguished from EBV-SMT by immunore-
activity for follicular dendritic cell markers CD23 and
CD35. Like EBV-SMT, FDC sarcoma usually demonstrates
immunoreactivity with the EBV receptor CD21. A dural-
based EBV-SMT must be distinguished from a meningioma.
There are many histologic variants of meningioma, but the
most common variants demonstrate whirling, round-to-
oval nuclei, some with intranuclear inclusions, eosinophilic
cytoplasm and indistinct cytoplasmic borders. Immunohis-
tochemically, meningiomas can be distinguished from EBV-
SMT as they are usually positive for EMA, but negative for
markers of smooth muscle.
3.7. Management and Outcome Data. Even though EBV-
SMTs frequently present with multiple lesions, their clinical
prognosis appears to be more favorable than conventional
LMS. Our review of the literature indicates that even EBV-
positiveleiomyomasintheseAIDspatientshavethepotential
to recur or behave aggressively, and that histologically
malignant-appearing tumors may respond well to therapy
and demonstrate a relatively favorable outcome. The his-
tologic features of EBV-SMT did not correlate well with
the clinical outcome [18, 26]. EBV-SMTs diagnosed as low-
grade smooth muscle neoplasms such as leiomyoma appear
to progress very slowly, even in the absence of treatment [32,
37]. Compared to conventional LMS that often progresses
withhematogenousspread and distantmetastasis, EBV-SMT
appears to be much less aggressive. Only 35% of patients
in these published cases died. Even then, death in these
patients was almost four times more likely to be attributed
to another condition (e.g., opportunistic infection) and not
the patient’s SMT. These case reports show that only four
patients with EBV-SMT died as a direct consequence of their
SMT. Moreover, it does not appear that the patient’s age,
gender, CD4 cell count, tumor type, tumor size, nor location
of their tumor had a noticeable impact on their outcome.
There was little diﬀerence between tumors that presented
within one year and after one year of an HIV diagnosis with
respect to the patient age, CD4 count, number of tumors or
patient outcome.
Data regarding treatment was available in 36 (56%)
patients. Surgical resection was the main therapeutic
approach in this published series. Complete remission was
achieved in two cases of unifocal EBV-SMT treated with
complete surgical excision and HAART [18]. Complete
surgical removal for EBV-SMT, however, was usually not
possible due to the multifocal nature of this condition. For
patients with leiomyomas, three tumors were resected and
no therapy was noted for one 5 year old male patient who
died 2 months after his diagnosis unrelated to his SMT.
In patients diagnosed with LMS, 11 underwent surgical
resection, including a splenectomy for one individual [12].
LMS was treated with radiation in three cases, two in
combination with resection [14, 16] and one together with
chemotherapy (gemcitabine)[7].EBV-SMT isreported tobe
resistant to cytotoxic chemotherapy, which may be poorly
tolerated by these severely immunocompromised patients
[7, 51]. While the impact of antiretroviral therapy could not
be evaluated because of limited published data, there are
rare published cases in which the patients’ tumor remained
stable in size or regressed even with a modest CD4 response
to highly active antiretroviral therapy (HAART) [4, 32, 42].
This is similar to the treatment of patients with PTLD,
whereimprovementoftheimmunestatusimprovesoutcome
in patients with EBV-SMT [4, 18]. In one case of LMS,
a 7-year-old-girl was treated with antiretrovirals only and
was alive with her tumor after 3 years of follow-up [42].
In 15 cases where the SMT was not further subtyped,
or called SMT-UMP (2 cases), therapy involved tumor
resection alone, except for one patient who had received
additional radiation for an incompletely resected dural SMT
[24].
Yin et al. recently reviewed the literature regarding
therapeutic strategies for treating leiomyoma and LMS in
children with AIDS. Based on the fact that there are no
randomized or clinical controlled trials and most of the data
is based on case reports and small series, they conclude that
it is likely best to treat each patient with a case-by-case
manner until larger, more rigorous studies are carried out
[57]. In some cases, conservative management and simple
observation alone may be appropriate for some of these
extremely ill patients [27, 32]. Newer studies have raised
the possibility ofusing EBV-speciﬁc immunotherapy, mTOR
inhibitors, and demethylating agents as possible therapeutic
options for EBV-SMT [51]. The mTOR pathway plays an
important role in regulating cell growth and proliferation
and its deregulation is associated with many human cancers
and diabetes. Sirolimus inhibits mTOR and may be a poten-
tial therapeutic alternative for cancers for which the mTOR-
Aktpathwayisactivated. Somesuccesshasbeenseentreating
EBV-SMT and Kaposi sarcoma with sirolimus [51–53].
Information about patient outcome was documented in
47 cases (73%),and is summarized in Table 5. Deathin these
published cases was three times more likely to be due to
another etiology than the patient’s SMT for both benign
and sarcomatous SMT. There did not appear to be any
appreciable diﬀerence among the various clinical outcomes
with respect to patient age or gender, CD4 cell count, tumor
type or size, nor location of tumor.8 Pathology Research International
Table 5: Outcome of SMT in HIV-infected patients.
Clinical outcome Number of
patients (N = 64)
Months recorded
average (range)
Alive with no evidence
of SMT 8 (13%) 9 (5–20)
Alive with SMT 19 (30%) 17 (0.5–60)
Died of SMT 4 (6%) 7 (4–12)
Died of other cause(s) 14 (22%) 3 (0–11)
Lost to follow up 2 (3%) Not applicable
No published data
available 17 (27%) Not applicable
LMS: leiomyosarcoma.
4.Conclusion
This paper oﬀers, to the best of our knowledge, the largest
analysis to date on cases of SMT arising in the setting of
HIV infection. This study is limited by the inclusion of only
English language articles. Also, the data may be biased by
the absence of published cases from regions of the world
(e.g., Africa) where the AIDS epidemic is rampant. This may
explain why the bulk of published cases were from the USA.
Nevertheless, analysis of these 53 published articles provides
someinsightintothepathologyandbehavioroftheseunique
tumors.Absenceofspeciﬁcdataelementsandtumorsubtype
in several articles may have limited some of the analyses.
There is no convincing evidence of viral integration into
the host (smooth muscle) genome. The presence of EBV
in SMT suggests a causal involvement of EBV in SMTs
in AIDS patients. The mode of EBV entry into smooth
muscle cells remains speculative. These data highlight the
variable aggressiveness and clinical outcome of EBV-SMT
arising in patients with AIDS. EBV-SMT should always be
included in the diﬀerential diagnosis for a mesenchymal
tumor arising in any organ in HIV-infected patients of
all ages. Further case reports are anticipated as the HIV
epidemic persists and awareness of these distinct tumors
grows [58]. As pathologists may not always know the
clinical history of immunosuppression, it may be wise to
includeEBV-SMT in the diﬀerential diagnosis ofany smooth
muscle tumor occurring in uncommon sites. Future work
should be directed at determining why certain individuals
are susceptible to EBV-mediated transformation. It also
remains to be seen what impact HAARThas on these unique
neoplasms and whether newly described lines of therapy
such as mTOR inhibitors and demethylating agents will
have beneﬁcial therapeutic eﬀects. Larger studies are needed
to improve our understanding and management of these
unique EBV-SMTs.
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